HOOKIPA plans voluntary delisting and deregistration ahead of asset sale to Gilead and dissolution

HOOKIPA Pharma Inc.

Intends to voluntarily delist from Nasdaq; Form 25 expected July 29, delisting effective ~August 8, 2025.
Will file Form 15 to deregister under Section 12(g) and suspend SEC reporting after delisting.
Delisting/deregistration tied to pending asset sale to Gilead for HB-400/HB-500 programs and planned dissolution.
Special meeting of stockholders set for July 29, 2025 to approve asset sale and dissolution.
Upon dissolution, proceeds from asset sale and other assets to be distributed to stockholders after liabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.